CytomX Therapeutics Receivables

CytomX Therapeutics (CTMX) currently reports a receivables of $37M as of June 2026. That compares with $1.9M in the prior-year period — up 1906.1% year over year. Use the charts on this page to explore CytomX Therapeutics's receivables history and peer comparisons.

CytomX Therapeutics's receivables increased from $1.9M to $37M — a 1906.1% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

CytomX Therapeutics reported $37M in receivables as of June 2026. That compares with $1.9M in the prior-year period — up 1906.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $37M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for CytomX Therapeutics, and consider following CTMX for alerts when major investors trade the stock.

CytomX Therapeutics is classified in the Healthcare sector. On receivables, it currently shows $37M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CTMX with unrelated industries.